What is Supernus Pharmaceuticals's finished goods?

Supernus Pharmaceuticals (SUPN) reported finished goods of $19.54M in Q1 2026.

How has Supernus Pharmaceuticals's finished goods changed year-over-year?

Supernus Pharmaceuticals's finished goods decreased by 11.5% year-over-year, from $22.07M to $19.54M.

What is the long-term trend for Supernus Pharmaceuticals's finished goods?

Over 5 years (2020 to 2025), Supernus Pharmaceuticals's finished goods has grown at a 4.3% compound annual growth rate (CAGR), from $17.13M to $21.12M.

Supernus Pharmaceuticals SUPN Finished goods

Finished goods at other companies

AbbVieABBV

——

Jazz PharmaceuticalsJAZZ

——

Other financials

Income statement

See full

Revenue$207.7M+38.6%

Gross profit$184.3M+37.5%

Operating income-$8.3M+18.8%

Net income-$2.3M+80.6%

EPS (diluted)-$0.04+81.0%

Balance sheet

See full

Cash & equivalents$186.3M+60.8%

Total debt$40.9M+26.6%

Total equity$1.1B+4.5%

Total assets$1.5B+11.4%

Cash flow

See full

Operating cash flow$66.5M+117%

CapEx--100%

Free cash flow$66.5M+120%

Valuation

See full

Market cap$2.58B+62.8%

Enterprise value$2.44B+62.3%

P/S3.3×+0.9×

Profitability

See full

Gross margin89.4%+1.0pp

Operating margin-7.8%-18.9pp

Net margin-3.7%-13.0pp

FCF margin27.9%+3.4pp

Returns & leverage

See full

Return on equity-2.8%-9.1pp

Debt / equity0×0.0×

Current ratio2×-0.5×

Where this comes from

Reported directly by Supernus Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:InventoryFinishedGoodsNetOfReserves.

The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Supernus Pharmaceuticals's finished goods.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Supernus Pharmaceuticals's finished goods?: Supernus Pharmaceuticals (SUPN) reported finished goods of $19.54M in Q1 2026.
How has Supernus Pharmaceuticals's finished goods changed year-over-year?: Supernus Pharmaceuticals's finished goods decreased by 11.5% year-over-year, from $22.07M to $19.54M.
What is the long-term trend for Supernus Pharmaceuticals's finished goods?: Over 5 years (2020 to 2025), Supernus Pharmaceuticals's finished goods has grown at a 4.3% compound annual growth rate (CAGR), from $17.13M to $21.12M.